Ipsen - Décembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information...
Ipsen - Bilan semestriel - 31 12 2024 Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF Boulogne-Billancourt (France), le...
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly...
Ipsen - Half year statement - 2024 12 31 Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF Boulogne-Billancourt (France...
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly...
Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information...
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Ipsen secures exclusive...
Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en...
Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T...
Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at...
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3...
Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP...
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus Ipsen...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads